Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Focal radiation boost nets better outcomes in prostate cancer
Key clinical point: Adding a focal boost to whole-prostate radiation therapy improves outcomes in men with intermediate- or high-risk prostate cancer without increasing late toxicity.
Major finding: The 5-year rate of biochemical disease–free survival was 92% with the addition of the focal boost to the visible tumor versus 85% with standard radiation therapy alone (P < .001).
Study details: A phase 3 randomized controlled trial of 571 men with intermediate- or high-risk prostate cancer (FLAME trial).
Disclosures: The trial was funded by the Dutch Cancer Society and Stand Up Against Cancer Belgium. The principal investigator disclosed no conflicts of interest.
De Boer HCJ et al. ESTRO 2020. Abstract OC-0612.